- Home
- / Equillium
Equillium
Stock Price
$1.4
2024-10-29
Market Capitalization
$48.7 M
2024-10-29
Revenue
$41.1 M
FY, 2024
Equillium Summary
Company Summary
- Overview
- Equillium is a biotechnology company developing products for autoimmune and inflammatory disorders. It offers Itolizumab, amonoclonal antibody that targets the CD6-ALCAM signaling pathway; EQ101, a tri-specific inhibitor of IL-2, IL-9, and IL-15, three inflammatory cytokines implicated in multiple diseases; EQ102, a selective inhibitor of IL-15 and IL-21 for treatment of gastrointestinal diseases.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- San Diego, CA, US | view all locations
- Website
- https://www.equilliumbio.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jason Keyes, Chief Financial Officer
Daniel M. Bradbury, Co-Founder, Executive Chairman
Stephen Connelly, Co-Founder, Chief Scientific Officer, Director
Operating MetricsView all
Trademarks (US)
2
Q1, 2023
Trademarks (Foreign)
1
Q1, 2023
Facility Space Leased, sq. ft.
1.8K
FY, 2022
LocationsView all
2 locations detected
San Diego, CA HQ
United States
2223 Avenida De La Playa, Suite 105
San Francisco, CA
United States
601 Gateway Blvd., Suite 1020
Equillium Financials
Summary Financials
- Net income (Q1, 2026)
- ($5.3M)
- Cash (Q1, 2026)
- $61.3M
- EBIT (Q1, 2026)
- ($5.6M)
- Enterprise value
- $19.1M